Demoly P, Dhivert-Donnadieu H, Bousquet J
Service des Maladies Respiratoires-INSERM U454-IFR3-Hôpital Arnaud de Villeneuve-CHU de Montpellier-34295 Montpellier.
Allerg Immunol (Paris). 2000 Dec;32(10):397-401.
Specific immunotherapy or allergen vaccination has been in routine use since 1911 for the treatment of respiratory allergic diseases. It is more effective in children and young adults than later in life. Its efficacy has been demonstrated in double-blind placebo controlled studies in both allergic rhinoconjunctivitis and allergic asthma. The improvement of allergenic extracts (in particular by standardization), the better understanding of the mechanisms of action of immunotherapy, the use of local administration routes and the publication of guidelines have legitimate its definite role to play in the therapeutic management of allergic respiratory diseases in childhood.
自1911年以来,特异性免疫疗法或变应原疫苗接种已被常规用于治疗呼吸道过敏性疾病。它在儿童和年轻人中比在生命后期更有效。其疗效已在变应性鼻结膜炎和过敏性哮喘的双盲安慰剂对照研究中得到证实。变应原提取物的改进(特别是通过标准化)、对免疫疗法作用机制的更好理解、局部给药途径的使用以及指南的发布,使其在儿童过敏性呼吸道疾病的治疗管理中发挥明确作用具有了合理性。